- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Mediators of Inflammation
Volume 2012 (2012), Article ID 956509, 11 pages
Oleic Acid Induces Lung Injury in Mice through Activation of the ERK Pathway
1Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz, FIOCRUZ, 21040-900 Rio de Janeiro, RJ, Brazil
2Departamento de Biologia Celular e Molecular, Instituto de Biologia, Universidade Federal Fluminense, 24020-15 Niterói, RJ, Brazil
3Departamento de Medicina Interna, Faculdade de Ciências Médicas, Universidade do Estado do Rio de Janeiro, 20550-900 Rio de Janeiro, RJ, Brazil
4Departamento de Biologia Celular, Instituto de Ciências Biológicas, Universidade de Juiz de Fora, 36036-900 Juiz de Fora, MG, Brazil
Received 23 August 2012; Accepted 18 October 2012
Academic Editor: Yves Denizot
Copyright © 2012 Cassiano Felippe Gonçalves-de-Albuquerque et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Oleic acid (OA) can induce acute lung injury in experimental models. In the present work, we used intratracheal OA injection to show augmented oedema formation, cell migration and activation, lipid mediator, and cytokine productions in the bronchoalveolar fluids of Swiss Webster mice. We also demonstrated that OA-induced pulmonary injury is dependent on ERK1/2 activation, since U0126, an inhibitor of ERK1/2 phosphorylation, blocked neutrophil migration, oedema, and lipid body formation as well as IL-6, but not IL-1β production. Using a mice strain carrying a null mutation for the TLR4 receptor, we proved that increased inflammatory parameters after OA challenges were not due to the activation of the TLR4 receptor. With OA being a Na/K-ATPase inhibitor, we suggest the possible involvement of this enzyme as an OA target triggering lung inflammation.
Adult respiratory distress syndrome (ARDS) description appeared in 1967, with 12 patients with refractory cyanosis to oxygenation therapy . Recently, a draft definition proposed 3 mutually exclusive categories of ARDS based on degree of hypoxemia: mild (200 mm Hg < PaO2/FIO2 ≤ 300 mm Hg), moderate (100 mm Hg < PaO2/FIO2 ≤ 200 mm Hg), and severe (PaO2/FIO2 ≤ 100 mm Hg)  which was nominated as Berlin definition, replacing the American-European consensus . The initial lesion characterizing the exudative phase of ARDS is an increase in alveolar permeability to plasma proteins, leading to an interstitial and alveolar oedema [4, 5]. In the acute phase, cytokines and lipids are released, leading to alveolar-capillary barrier loss with hyaline membrane formation [6, 7]. In fact, ARDS is a diffuse alveolar damage secondary to an intense lung inflammatory response to an infectious, noninfectious, or extra pulmonary insult [8, 9].
ARDS can be induced by several factors such as systemic endotoxin release, pneumonia, drug overdose, acid aspiration, fat embolism, and pancreatitis [10–13] and can occur in pathological processes including sepsis, major trauma, or severe leptospirosis [8, 14, 15].
Resolution of the pulmonary oedema and lung inflammation are important determinants of ARDS outcome. Removal of alveolar fluid depends on transport of salt and water across the alveolar epithelium through apical sodium channels (ENaC) followed by extrusion to the lung interstitium via the Na-K-ATPase of alveolar epithelial cells [16–18]. Oleic acid (OA) is an inhibitor of the Na/K-ATPase activity in bovine serum  and is also a Na/K-ATPase inhibitor in a rabbit lung model, increasing endothelial permeability . OA has been reported to induce ARDS in experimental models  and lung injury correlates with elevated free fatty acid levels . Furthermore, plasma and bronchoalveolar lavage fluid (BALF) from ARDS patients presented elevated OA levels [23, 24].
Lipopolysaccharide (LPS), an outer membrane component of Gram-negative bacteria, can cause serious multiple organ dysfunctions, particularly in the respiratory system . LPS induces inflammation through the MAPKinase ERK1/2 activation. The ERK pathway participates in chemoattractant-induced neutrophil chemotaxis, in the respiratory burst  and in LPS-induced ARDS [27, 28]. The attenuation of ERK1/2 phosphorylation in neutrophils by luteolin has protected against the LPS-induced ARDS . In alveolar macrophages, the combined inhibition of p38 and ERK1/2 induced a suppression of cytokine release . In this respect, OA induces activation of the ERK1/2 pathway in a certain type of breast cancer cell .
We used a mouse model of OA-induced ARDS to study the involvement of ERK pathway in lung inflammation. We measured lung oedema, cell migration and activation, lipid mediator and cytokine production, lung morphological alterations, and the response to a respiratory functional test.
2. Materials and Methods
We used male mice (30–35 g) of the following strains: Swiss Webster (SW), C57Bl/10 (from the Oswaldo Cruz Foundation Breeding Unit, Rio de Janeiro, RJ, Brazil) and C57Bl/10ScCr (kindly provided by the Federal Fluminense University Breeding Unit, RJ, Rio de Janeiro, Brazil). Animals were lodged at 22°C with a 12 h light/dark cycle and free access to food and water. Animal housing conditions and experimental procedures conformed to institutional regulations and were in accordance with the National Institute of Health guidelines on animal care. The institutional Animal Welfare Committee approved all procedures described here under license number 002-08.
2.2. Preparation of Oleate Solutions
We used OA (from Sigma Chemicals) to prepare a 100 mM trisoleate solution. After weighting and water addition, trispowder (Trizma base-Sigma) was slowly added until the pH reached 10.0. This mixture was sonicated and, after complete oleate solubilization, the pH was carefully adjusted to 7.6 with diluted HCl. Working oleate solutions were prepared by appropriate dilutions of the 100 mM solution with sterile saline (PBS) pH 7.4.
2.3. Intratracheal Oleate or LPS Administration
After isoflurane anesthesia, an incision above thyroid was made to expose the trachea. Trisoleate (1.25 μmol in 0.05 mL), LPS (500 ng in 0.05 mL), or the same volume of saline (in controls) were instilled into the trachea of each mouse with an insulin syringe. After suturing the incision with a 3.0 silk thread, mice were returned to their cage and monitored until complete recovering from surgery. Inflammatory parameters were measured at different times after challenges.
2.4. Total and Differential Cell Analysis in Bronchoalveolar Lavage Fluid (BALF)
After isolating the trachea by blunt dissection, 1.0 mL volume of PBS was instilled in each animal through a small caliber tube inserted into the airway. After gentle aspiration, 1 mL was recovered in each instillation/aspiration cycle. Total leukocyte counts were performed by microscopy in Neubauer chambers after diluting BALF samples in Türk solution (2% acetic acid). Differential leukocyte counts were done in cytocentrifuged smears stained with the May-Grunwald-Giemsa method. Total protein in BALF supernatants was determined using the Micron BCA Kit method (Pierce) according to the manufacturer’s instructions.
2.5. Lipid Body Staining and Counting
While still moist, leukocytes on cytospin slides were fixed in 3.7% formaldehyde in Ca2+, Mg2+-free Hank’s buffered salt solution ((HBSS), pH 7.4) and stained with 1.5% OsO4 . Lipid bodies were enumerated by microscopy with oil-immersion objective lens in 50 consecutively scanned leukocytes.
2.6. Cytokine/Chemokine Assays
Measurements of IL-6, CCL3/MIP-1α, TNFα, and IL-1β were done on cell-free BALF supernatants using ELISA kits, in accordance with the manufacturer’s instructions (Duo Set, R&D Systems, Minneapolis, MN, USA).
2.7. PGE2 and LTB4 Assays
LTB4 and PGE2 in BALF supernatants were assayed by enzyme immunoassay (EIA) kits according to the manufacturer’s instructions (Cayman Chemical, Ann Arbor, MI, USA).
2.8. Morphologic Studies
24 h after the challenge with trisoleate or saline, animals were euthanized in a CO2 chamber and lungs were removed. For microscopy studies, lungs were fixed in 10% neutral buffered formalin, embedded in paraffin, sectioned at 4 μm, and stained with hematoxylin and eosin.
2.9. Cell Culture Experiments
A549 lung epithelial cells were kindly provided by Dr. Cristina Plotkowski (from the Rio de Janeiro State University, Rio de Janeiro, RJ, Brazil). They were maintained in a complete DMEM/F12 (Hyclone) medium (containing 2% fetal bovine serum, 1% penicillin, and 100 UI/mL streptomycin). A day before the experiment, cells were treated with trypsin (0,025%), centrifuged at 4°C, 400 ×g for 10 min, resuspended in the complete medium, and incubated at 37°C in 5% CO2 in 24 well plates (300,000 cells per well). We tested two different OA concentrations (100 and 250 μM in the final incubation volume). Cells were washed with PBS 30 min after the stimulus, lysed with lysis buffer (10 mM Tris pH 8.0, 150 mM NaCl, 1% Triton) containing protease inhibitors (Complete Protease Inhibitor Cocktail Tablets from Roche), and stored at −20°C.
2.10. Lung Tissue Experiments
Animals were anesthetized with ketamine and xylazine and then perfused with 20 mL of 20 mM ethylenediaminetetraacetic acid (EDTA) pH 7.4 through the right cardiac ventricle. Then, lung tissues cut into small pieces were homogenized at 4°C in a homogenizer using the lysis buffer containing protease inhibitors.
2.11. Evaluation of ERK1/2 Activation in Cultured Cells and Lung Tissues
Suspensions of cell and lung lysates in the electrophoresis sample buffer were heated at 100°C for 5 min and run in 10% polyacrylamide gels (PAGE-SDS). After transfer of gel proteins to nitrocellulose membranes under 15 V during 60 min (Biorad semidry system), membranes were incubated with a blocking solution followed by incubation with the monoclonal antibody antiphosphorylated ERK1/2 (Cell Signaling—1 : 1000 dilution) and then with the antimouse peroxidase conjugated antibody (Pierce, 1 : 10.000). The detection was performed with the “Super Signal Chemiluminescence” kit (Pierce), exposing the membrane to an autoradiograph film (Kodak MR Biomax). Membranes containing proteins were stripped, blocked again, and incubated with the monoclonal antibody antitotal ERK1/2 (Cell Signaling—1 : 1000) followed by treatment with antimouse antibody conjugated to peroxidase. After digitalized and analyzed by size and intensity by the Image Master 2D Elite 4.01 equipment, bands were compared to controls and normalized against total ERK1/2. Results’ expression was in folds over controls.
2.12. Treatment with a MAP Kinase ERK1/2 Phosphorylation Inhibitor
In “in vivo” experiments, the ERK1/2 phosphorylation inhibitor U0126 (10 mg/kg), (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio] butadiene) highly selective inhibitor of ERK 1 and ERK 2, was injected by the intraperitoneal route 30 min before OA administration. U0126 was previously dissolved in dimethylsulphoxide (DMSO) and diluted with PBS when used.
2.13. Statistical Analysis
Results were expressed as mean ± SEM and analyzed by the Newman-Keuls-Student test. Differences were considered significant when .
We used a mouse model of ARDS consequent to an intratracheal (IT) injection of oleic acid and showed that OA stimulation (1.25 μmol per mouse, approximately 10 mg/kg of body weight) induced an intense neutrophil infiltration in SW mice. Cell migration was detected already at 6 h, peaked at 24 h, returning to basal levels at 48 h (Figure 1(a)). BALF total protein concentration, an indicator of oedema formation, increased in the first 6 h, remained high at 24 h and 48 h, but decreased thereafter (Figure 1(b)).
Lipid body formation, indicating cell activation, increased in BALF leukocytes 6 h (Figure 2(a)) and 24 h (Figure 2(b)) after OA administration. The lipid mediator LTB4 was significantly increased in BALF supernatant 6 h after the OA challenge (Figure 2(c)), decreasing to basal levels at 24 h (Figure 2(d)), while PGE2 reached its peak at 24 h (Figure 2(e)). In addition to inflammatory lipid mediators, we also measured cytokine concentrations (IL-1β, IL-6, TNFα, and MIP-1α) in BALF, showing that they were augmented 24 h after the OA stimulus (Figures 2(f), 2(g), 2(h), and 2(i), resp.).
We then compared OA and LPS challenges in C57BL10/ScCr and the corresponding wild-type C57BL10. C57BL10/ScCr mice possess a null mutation for TLR4 and are resistant to high LPS doses . As expected, the wild-type strain showed a typical response to LPS, presenting cell migration and increased total protein in BALF, while the C57BL10/ScCr did not respond to LPS. On the other hand, OA not only induced cell migration but also augmented the total BALF protein in both animal types, as shown in Figures 3(a) and 3(b) then excluding a possible oleic acid contamination with LPS.
In Figures 4(a) and 4(b), macroscopic photos clearly show an intense hemorrhage in SW animals 24 hours after the OA injection, as compared to controls, while microscopic analyses (Figures 4(c) and 4(d)) of these lungs revealed an intense alveolar hemorrhage. Functional analysis by lung plethysmography using buxco revealed an altered pulmonary function 24 h after OA treatment (Figure 4(e)).
We next evaluated the intracellular signaling mechanism involved in OA-induced inflammation. In our experiments, OA caused a substantial increase in MAPK ERK1/2 phosphorylation both in vivo and in vitro. Analysis of lung tissues 4 hours after IT injection of OA showed a marked increase in ERK1/2 phosphorylation. Cultured lung epithelial A549 cells also increased ERK1/2 phosphorylation after stimulation with OA (Figure 5).
The role of ERK1/2 activation in our model was investigated by treating animals with the inhibitor of ERK1/2 phosphorylation U0126. Pretreating OA stimulated-SW mice with U0126 reduced significantly BALF inflammatory parameters as neutrophil migration (Figure 6(a)), lipid body formation (Figure 6(b)), and IL-6 synthesis (Figure 6(c)). IL-1β production (Figure 6(d)) was an exception, showing no significant reduction in U0126-treated animals.
In ARDS, neutrophil is the main cell migrating to lung [8, 34]. When activated, neutrophils release an arsenal of potent molecules contributing to increased tissue damage and inflammation . In our experiments, neutrophil infiltration was already detected 6 h after OA injection, reaching a peak at 24 h and decaying to the basal level, thereafter indicating the resolution of the inflammatory process.
ARDS is described as an increase in endothelial permeability  and a loss of epithelial barrier function [13, 36], leading to pulmonary oedema. In ARDS, the transport capacity of the alveolar epithelium is greatly diminished and is correlated to a high mortality rate [37, 38]. Actions improving oedema clearance can offer important therapeutic options for patients with acute respiratory insufficiency. Na+ channels are pivotal in the control of Na+ clearance and recent data indicated that the increment of the Na/K-ATPase activity in type II cells was enough to increase the resolution of the alveolar fluid [16, 18, 39, 40]. Sodium channels contribute to alveolar fluid clearance under physiological conditions and the deregulation of the sodium channel activity might contribute to the pathogenesis of the pulmonary oedema . OA is an Na/K-ATPase inhibitor [42–44] and also a sodium channel inhibitor . Therefore, we suggest that, in our model, these mechanisms are involved in lung oedema formation.
Cytokines such as TNF-α and interleukins (mainly IL-1β and IL-6) are important mediators in the development of ARDS , contributing to augmented vascular permeability and organ dysfunction . IL-6 release seems to play a key role in ARDS  since IL-6 levels were found significantly higher in patients with subsequent ARDS than in patients who did not develop it , although its detailed mechanism of action remains unclear . Accordingly, our results showed, in BALF supernatants of OA challenged animals, increased IL-6, IL-1β, and TNF-α production. The chemokine MIP-1α, a chemotactic factor for monocytes , was also increased, showing that intratracheal challenge with OA induces the main inflammatory mediators involved in clinical ARDS. The resulting inflammation could lead to the altered lung function seen by plethysmography.
Lipid bodies are cytoplasmic inclusions present in different cellular types . In limited number, they are normal constituents of some cells, but they increase in number and size in those involved in inflammatory and immunologic processes [51, 52]. Lipid bodies generate the lipid mediators LTB4 and PGE2 . In our model, oleic acid augmented the lipid body number as earlier as 6 hours after OA challenge, remaining high at 24 hours. Moreover, LTB4, a potent chemotactic agent for neutrophils , increased as early as 6 hours and could be the mediator involved in neutrophil migration into the lung in our model, returning to basal levels at 24 hours. PGE2 production was elevated 24 hours after OA challenge. In this regard, accumulating evidence suggests that the cyclooxygenase-2 (COX-2)/PGE2 pathway plays an important role in augmenting inflammatory immune response in sepsis-associated ARDS, since the inhibition of lung PGE2 production inhibits oedema, neutrophil infiltration, proinflammatory cytokine production, adhesion molecules expression, and restored lung morphology, increasing survival in polymicrobial sepsis . Furthermore, this mediator inhibited phagocytosis and in vitro killing by alveolar macrophages, impaired lung recruitment of polymorphonuclear leukocytes, and also the clearance of Streptococcus pneumoniae .
In severe ARDS, hemorrhage can be present, as seen in patients with severe leptospirosis, leading to high mortality rates as a result of lung flooding and inflammation [56, 57]. Here we showed that hemorrhage was detected macroscopically and microscopically after OA challenge.
Toll-like receptors (TLR) participate in the detection of microorganisms. TLR4 is the ligand for LPS found in Gram-negative bacteria . Using a mice strain carrying a null TLR4 mutation and comparing with its wild-type strain, we showed that OA was not acting through TLR4 activation. Therefore, oleic-acid-induced lung injury was not due to a LPS contamination of the oleic acid solution.
Extracellular signal-regulated protein kinase (ERK) was the first MAPK protein to be identified  and was subsequently shown to be involved in cell proliferation and activation . In fact, OA induced ERK/MAPK phosphorylation in breast cancer cells  and also vascular smooth muscle cell proliferation and migration by a direct ERK-dependent mitogenic response [61, 62]. ERK is involved in regulating proinflammatory mediator production [30, 63]. We tested if OA could induce ERK1/2 phosphorylation in our model and this was effectively true not only in the lung tissue of mice, but also in cultured A549 epithelial lung cells. Specific inhibitor of RAS/ERK activity suppressed TGF-β1 production induced by oxidized low-density lipoprotein in human alveolar epithelial cells  and the U0126, a selective inhibitor of the mitogen-activated protein kinases MEK-1 and MEK-2, upregulated aquaporin 4 expression in alveolar type II cells in rats with oleic acid-induced lung injury . We, therefore, investigated the impact of blocking ERK1/2 activation in OA-challenged mice, using the drug U0126 that inhibits the ERK phosphorylation step. Our results show that, in OA-challenged animals, ERK1/2 inhibition blocked neutrophil migration, oedema (data not shown), and lipid body formation as well as IL-6, but not IL-1β production. Since animals received OA directly into the lung, the direct epithelial cell damage due to the presence of this fatty acid could in part provoke lung injury. Nevertheless, the fact that U0126 inhibited OA-induced lung inflammation may argue against this possibility.
Considering that OA-induced inflammation is independent of TLR4 stimulation, a question rises about the primordial mechanism leading to ERK activation. Whereas OA is a Na/K-ATPase inhibitor, as already stated in the introductory section, and taking into account the signaling properties of this enzyme  promoting MAP kinase activation, including ERK , we suggest that Na/K-ATPase could be the initial OA target.
IL-1β and IL-18 are produced as cytosolic precursors and they typically require secondary proteolytic cleavage induced by inflammasome for activation and secretion . The inflammasome consists of several proteins, one of them, NLRP3, is involved in the recognition of bacterial RNA, ATP, uric acid, and low intracellular potassium concentration  which is a consequence of Na/K-ATPase inhibition by OA . A recent communication showed that the leptospiral glycolipoprotein (GLP), which is also a specific Na/K-ATPase inhibitor [42, 43], activated the NLRP3 inflammasome by downregulating the Na/K-pump . The inflammasome is an important step in IL-1β release, and, in our results, the IL-1β production was independent of ERK inhibition by U0126, pointing out, therefore, to a mechanism independent of ERK activation.
In conclusion, activation of the ERK signaling pathway independently of TLR4 stimulation is crucial in OA-induced lung injury. Furthermore, the participation of the Na/K-ATPase as a primary OA target in the mechanism of ERK activation is suggested.
|OA:||Oleic acid (18 : 1n-9)|
|ERK:||Extracellular signal-regulated kinases|
|Na/K-ATPase:||Sodium potassium ATPase pump|
|ARDS:||Acute respiratory distress syndrome|
|BALF:||Bronchoalveolar lavage fluid|
|TNF:||Tumor necrosis factor|
|MIP-1α:||Macrophage inflammatory protein 1 alpha.|
Conflict of Interests
The authors declare that they do not have any conflict of interests.
This work received financial supports from Fundação de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ), Programa Estratégico de Apoio à Pesquisa em Saúde (PAPES), FIOCRUZ, and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). The authors acknowledge the following institutions where this work was accomplished: Fundação Oswaldo Cruz (FIOCRUZ), Universidade do Estado do Rio de Janeiro (UERJ), and Universidade Federal Fluminense (UFF).
- D. G. Ashbaugh, D. B. Bigelow, T. L. Petty, and B. E. Levine, “Acute respiratory distress in adults,” The Lancet, vol. 2, no. 7511, pp. 319–323, 1967.
- V. M. Ranieri, G. D. Rubenfeld, B. T. Thompson et al., “Acute respiratory distress syndrome: the Berlin definition,” JAMA, vol. 307, no. 23, pp. 2526–2533, 2012.
- G. R. Bernard, A. Artigas, K. L. Brigham et al., “The American-European Consensus Conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination,” American Journal of Respiratory and Critical Care Medicine, vol. 149, no. 3, pp. 818–824, 1994.
- S. E. Orfanos, I. Mavrommati, I. Korovesi, and C. Roussos, “Pulmonary endothelium in acute lung injury: from basic science to the critically ill,” Intensive Care Medicine, vol. 30, no. 9, pp. 1702–1714, 2004.
- M. A. Matthay and R. L. Zemans, “The acute respiratory distress syndrome: pathogenesis and treatment,” Annual Review of Pathology, vol. 6, pp. 147–163, 2011.
- L. Nieuwenhuizen, P. G. De Groot, J. C. Grutters, and D. H. Biesma, “A review of pulmonary coagulopathy in acute lung injury, acute respiratory distress syndrome and pneumonia,” European Journal of Haematology, vol. 82, no. 6, pp. 413–425, 2009.
- W. Y. Park, R. B. Goodman, K. P. Steinberg et al., “Cytokine balance in the lungs of patients with acute respiratory distress syndrome,” American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 10, part 1, pp. 1896–1903, 2001.
- L. B. Ware and M. A. Matthay, “The acute respiratory distress syndrome,” The New England Journal of Medicine, vol. 342, no. 18, pp. 1334–1349, 2000.
- C. Pierrakos, M. Karanikolas, S. Scolletta, et al., “Acute respiratory distress syndrome: pathophysiology and therapeutic options,” Journal of Clinical Medicine and Research, vol. 4, no. 1, pp. 7–16, 2012.
- A. Artigas, G. R. Bernard, J. Carlet et al., “The American-European consensus conference on ARDS, part 2: ventilatory, pharmacologic, supportive therapy, study design strategies, and issues related to recovery and remodeling,” American Journal of Respiratory and Critical Care Medicine, vol. 157, no. 4, pp. 1332–1347, 1998.
- A. M. Brackenbury, P. S. Puligandla, L. A. McCaig et al., “Evaluation of exogenous surfactant in HCl-induced lung injury,” American Journal of Respiratory and Critical Care Medicine, vol. 163, no. 5, pp. 1135–1142, 2001.
- H. R. Gossling and T. A. Donohue, “The fat embolism syndrome,” Critical Care Medicine, vol. 31, no. 9, pp. 2355–22363, 2003.
- M. A. Matthay and G. A. Zimmerman, “Acute lung injury and the acute respiratory distress syndrome: four decades of inquiry into pathogenesis and rational management,” American Journal of Respiratory Cell and Molecular Biology, vol. 33, no. 4, pp. 319–327, 2005.
- K. G. Davidson, A. D. Bersten, H. A. Barr, K. D. Dowling, T. E. Nicholas, and I. R. Doyle, “Lung function, permeability, and surfactant composition in oleic acid-induced acute lung injury in rats,” American Journal of Physiology, vol. 279, no. 6, pp. L1091–L1102, 2000.
- K. G. Davidson, A. D. Bersten, H. A. Barr, K. D. Dowling, T. E. Nicholas, and I. R. Doyle, “Endotoxin induces respiratory failure and increases surfactant turnover and respiration independent of alveolocapillary injury in rats,” American Journal of Respiratory and Critical Care Medicine, vol. 165, no. 11, pp. 1516–1525, 2002.
- J. I. Sznajder, P. Factor, and D. H. Ingbar, “Invited review: lung edema clearance: role of Na+-K+-ATPase,” Journal of Applied Physiology, vol. 93, no. 5, pp. 1860–1866, 2002.
- I. Vadász, R. E. Morty, A. Olschewski et al., “Thrombin impairs alveolar fluid clearance by promoting endocytosis of Na+,K+-ATPase,” American Journal of Respiratory Cell and Molecular Biology, vol. 33, no. 4, pp. 343–354, 2005.
- M. A. Matthay, H. G. Folkesson, and C. Clerici, “Lung epithelial fluid transport and the resolution of pulmonary edema,” Physiological Reviews, vol. 82, no. 3, pp. 569–600, 2002.
- D. M. Tal, M. D. Yanuck, G. Van Hall, and S. J. D. Karlish, “Identification of Na+/K+-ATPase inhibitors in bovine plasma as fatty acids and hydrocarbons,” Biochimica et Biophysica Acta, vol. 985, no. 1, pp. 55–59, 1989.
- I. Vadász, R. E. Morty, M. G. Kohstall et al., “Oleic acid inhibits alveolar fluid reabsorption: a role in acute respiratory distress syndrome?” American Journal of Respiratory and Critical Care Medicine, vol. 171, no. 5, pp. 469–479, 2005.
- D. P. Schuster, “ARDS: clinical lessons from the oleic acid model of acute lung injury,” American Journal of Respiratory and Critical Care Medicine, vol. 149, no. 1, pp. 245–260, 1994.
- H. R. Rosen and H. Tuchler, “Pulmonary injury in acute experimental pancreatitis correlates with elevated levels of free fatty acids in rats,” HPB Surgery, vol. 6, no. 2, pp. 79–90, 1992.
- G. J. Quinlan, N. J. Lamb, T. W. Evans, and J. M. C. Gutteridge, “Plasma fatty acid changes and increased lipid peroxidation in patients with adult respiratory distress syndrome,” Critical Care Medicine, vol. 24, no. 2, pp. 241–246, 1996.
- S. L. Bursten, D. A. Federighi, P. E. Parsons et al., “An increase in serum C18 unsaturated free fatty acids as a predictor of the development of acute respiratory distress syndrome,” Critical Care Medicine, vol. 24, no. 7, pp. 1129–1136, 1996.
- S. H. J. Mei, S. D. McCarter, Y. Deng, C. H. Parker, W. C. Liles, and D. J. Stewart, “Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin,” PLoS Medicine, vol. 4, no. 9, article e269, 2007.
- M. Kuroki and J. T. O'Flaherty, “Differential effects of a mitogen-activated protein kinase kinase inhibitor on human neutrophil responses to chemotactic factors,” Biochemical and Biophysical Research Communications, vol. 232, no. 2, pp. 474–477, 1997.
- J. A. Nick, S. K. Young, K. K. Brown et al., “Role of p38 mitogen-activated protein kinase in a murine model of pulmonary inflammation,” Journal of Immunology, vol. 164, no. 4, pp. 2151–2159, 2000.
- K. Schuh and A. Pahl, “Inhibition of the MAP kinase ERK protects from lipopolysaccharide-induced lung injury,” Biochemical Pharmacology, vol. 77, no. 12, pp. 1827–1834, 2009.
- J. P. Lee, Y. C. Li, H. Y. Chen et al., “Protective effects of luteolin against lipopolysaccharide-induced acute lung injury involves inhibition of MEK/ERK and PI3K/Akt pathways in neutrophils,” Acta Pharmacologica Sinica, vol. 31, no. 7, pp. 831–838, 2010.
- D. Jarrar, J. F. Kuebler, L. W. Rue et al., “Alveolar macrophage activation after trauma-hemorrhage and sepsis is dependent on NF-κB and MAPK/ERK mechanisms,” American Journal of Physiology, vol. 283, no. 4, pp. L799–L805, 2002.
- A. Soto-Guzman, T. Robledo, M. Lopez-Perez, and E. P. Salazar, “Oleic acid induces ERK1/2 activation and AP-1 DNA binding activity through a mechanism involving Src kinase and EGFR transactivation in breast cancer cells,” Molecular and Cellular Endocrinology, vol. 294, no. 1-2, pp. 81–91, 2008.
- P. T. Bozza, J. L. Payne, S. G. Morham, R. Langenbach, O. Smithies, and P. F. Weller, “Leukocyte lipid body formation and eicosanoid generation: cyclooxygenase-independent inhibition by aspirin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 20, pp. 11091–11096, 1996.
- A. Poltorak, X. He, I. Smirnova et al., “Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene,” Science, vol. 282, no. 5396, pp. 2085–2088, 1998.
- D. L. Chen and D. P. Schuster, “Positron emission tomography with [18F]fluorodeoxyglucose to evaluate neutrophil kinetics during acute lung injury,” American Journal of Physiology, vol. 286, no. 4, pp. L834–L840, 2004.
- N. A. Maniatis, A. Kotanidou, J. D. Catravas, and S. E. Orfanos, “Endothelial pathomechanisms in acute lung injury,” Vascular Pharmacology, vol. 49, no. 4–6, pp. 119–133, 2008.
- M. A. Matthay, “The adult respiratory distress syndrome: definition and prognosis,” Clinics in Chest Medicine, vol. 11, no. 4, pp. 575–580, 1990.
- M. A. Matthay and J. P. Wiener-Kronish, “Intact epithelial barrier function is critical for the resolution of alveolar edema in humans,” American Review of Respiratory Disease, vol. 142, no. 6, part 1, pp. 1250–1257, 1990.
- L. B. Ware and M. A. Matthay, “Alveolar fluid clearance is impaired in the majority of patients with acute lung injury and the acute respiratory distress syndrome,” American Journal of Respiratory and Critical Care Medicine, vol. 163, no. 6, pp. 1376–1383, 2001.
- Z. S. Azzam, V. Dumasius, F. J. Saldias, Y. Adir, J. I. Sznajder, and P. Factor, “Na,K-ATPase overexpression improves alveolar fluid clearance in a rat model of elevated left atrial pressure,” Circulation, vol. 105, no. 4, pp. 497–501, 2002.
- M. Stern, K. Ulrich, C. Robinson et al., “Pretreatment with cationic lipid-mediated transfer of the Na+K+-ATPase pump in a mouse model in vivo augments resolution of high permeability pulmonary oedema,” Gene Therapy, vol. 7, no. 11, pp. 960–966, 2000.
- M. Althaus, W. G. Clauss, and M. Fronius, “Amiloride-sensitive sodium channels and pulmonary edema,” Pulmonary Medicine, vol. 2011, Article ID 830320, 8 pages, 2011.
- P. Burth, M. Younes-Ibrahim, F. H. F. S. Goncalez, E. R. Costa, and M. V. C. Faria, “Purification and characterization of a Na+,K+ ATPase inhibitor found in an endotoxin of Leptospira interrogans,” Infection and Immunity, vol. 65, no. 4, pp. 1557–1560, 1997.
- M. Younes-Ibrahim, B. Buffin-Meyer, L. Cheval et al., “Na,K-ATPase: a molecular target for Leptospira interrogans endotoxin,” Brazilian Journal of Medical and Biological Research, vol. 30, no. 2, pp. 213–223, 1997.
- H. G. P. Swarts, F. M. A. H. Schuurmans Stekhoven, and J. J. H. H. M. De Pont, “Binding of unsaturated fatty acids to Na+,K+-ATPase leading to inhibition and inactivation,” Biochimica et Biophysica Acta, vol. 1024, no. 1, pp. 32–40, 1990.
- B. W. Sears, M. D. Stover, and J. Callaci, “Pathoanatomy and clinical correlates of the immunoinflammatory response following orthopaedic trauma,” Journal of the American Academy of Orthopaedic Surgeons, vol. 17, no. 4, pp. 255–265, 2009.
- F. Martín, F. Santolaria, N. Batista et al., “Cytokine levels (IL-6 and IFN-γ), acute phase response and nutritional status as prognostic factors in lung cancer,” Cytokine, vol. 11, no. 1, pp. 80–86, 1999.
- A. Takala, I. Jousela, O. Takkunen et al., “A prospective study of inflammation markers in patients at risk of indirect acute lung injury,” Shock, vol. 17, no. 4, pp. 252–257, 2002.
- Y. Imai, K. Kuba, G. G. Neely et al., “Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury,” Cell, vol. 133, no. 2, pp. 235–249, 2008.
- M. Brueckmann, U. Hoffmann, E. Dvortsak et al., “Drotrecogin alfa (activated) inhibits NF-kappa B activation and MIP-1-alpha release from isolated mononuclear cells of patients with severe sepsis,” Inflammation Research, vol. 53, no. 10, pp. 528–533, 2004.
- A. M. Dvorak, E. Morgan, R. P. Schleimer, S. W. Ryeom, L. M. Lichtenstein, and P. F. Weller, “Ultrastructural immunogold localization of prostaglandin endoperoxide synthase (cyclooxygenase) to non-membrane-bound cytoplasmic lipid bodies in human lung mast cells, alveolar macrophages, Type II pneumocytes, and neutrophils,” Journal of Histochemistry and Cytochemistry, vol. 40, no. 6, pp. 759–769, 1992.
- A. M. Dvorak, H. F. Dvorak, and S. P. Peters, “Lipid bodies: cytoplasmic organelles important to arachidonate metabolism in macrophages and mast cells,” Journal of Immunology, vol. 131, no. 6, pp. 2965–2976, 1983.
- P. T. Bozza and J. P. B. Viola, “Lipid droplets in inflammation and cancer,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 82, no. 4–6, pp. 243–250, 2010.
- B. Samuelsson, S. E. Dahlen, and J. A. Lindgren, “Leukotrienes and lipoxins: structures, biosynthesis, and biological effects,” Science, vol. 237, no. 4819, pp. 1171–1176, 1987.
- S.-F. Ang, S. W. S. Sio, S. M. Moochhala, P. A. MacAry, and M. Bhatia, “Hydrogen sulfide upregulates cyclooxygenase-2 and prostaglandin E metabolite in sepsis-evoked acute lung injury via transient receptor potential vanilloid type 1 channel activation,” Journal of Immunology, vol. 187, no. 9, pp. 4778–4787, 2011.
- A. I. Medeiros, C. H. Serezani, S. P. Lee, and M. Peters-Golden, “Efferocytosis impairs pulmonary macrophage and lung antibacterial function via PGE2/EP2 signaling,” Journal of Experimental Medicine, vol. 206, no. 1, pp. 61–68, 2009.
- E. Marchiori, S. Lourenço, S. Setúbal, G. Zanetti, T. D. Gasparetto, and B. Hochhegger, “Clinical and imaging manifestations of hemorrhagic pulmonary leptospirosis: a state-of-the-art review,” Lung, vol. 189, no. 1, pp. 1–9, 2011.
- P. C. F. Marotto, A. I. Ko, C. Murta-Nascimento et al., “Early identification of leptospirosis-associated pulmonary hemorrhage syndrome by use of a validated prediction model,” Journal of Infection, vol. 60, no. 3, pp. 218–223, 2010.
- R. Medzhitov, P. Preston-Hurlburt, and C. A. Janeway Jr., “A human homologue of the Drosophila toll protein signals activation of adaptive immunity,” Nature, vol. 388, no. 6640, pp. 394–397, 1997.
- M. Krishna and H. Narang, “The complexity of mitogen-activated protein kinases (MAPKs) made simple,” Cellular and Molecular Life Sciences, vol. 65, no. 22, pp. 3525–3544, 2008.
- E. K. Kim and E. J. Choi, “Pathological roles of MAPK signaling pathways in human diseases,” Biochimica et Biophysica Acta, vol. 1802, no. 4, pp. 396–405, 2010.
- B. M. Egan, G. Lu, and E. L. Greene, “Vascular effects of non-esterified fatty acids: implications for the cardiovascular risk factor cluster,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 60, no. 5-6, pp. 411–420, 1999.
- G. Lu, T. A. Morinelli, K. E. Meier, S. A. Rosenzweig, and B. M. Egan, “Oleic acid-induced mitogenic signaling in vascular smooth muscle cells: a role for protein kinase C,” Circulation Research, vol. 79, no. 3, pp. 611–618, 1996.
- L.-L. Guo, Y.-J. Chen, T. Wang et al., “Ox-LDL-induced TGF-β1 production in human alveolar epithelial cells: involvement of the Ras/ERK/PLTP pathway,” Journal of Cellular Physiology, vol. 227, no. 9, pp. 3185–3191, 2012.
- C. L. Chen, T. P. Li, and L. H. Zhu, “Effect of MAPK signal transduction pathway inhibitor U0126 on aquaporin 4 expression in alveolar type II cells in rats with oleic acid-induced acute lung injury,” Nan Fang Yi Ke Da Xue Xue Bao, vol. 29, no. 8, pp. 1525–1528, 2009.
- Z. Xie and T. Cai, “Na+-K+-ATPase-mediated signal transduction: from protein interaction to cellular function,” Molecular Interventions, vol. 3, no. 3, pp. 157–168, 2003.
- A. Edwards and T. L. Pallone, “Ouabain modulation of cellular calcium stores and signaling,” American Journal of Physiology, vol. 293, no. 5, pp. F1518–F1532, 2007.
- F. Martinon, K. Burns, and J. Tschopp, “The Inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β,” Molecular Cell, vol. 10, no. 2, pp. 417–426, 2002.
- S. Akira, S. Uematsu, and O. Takeuchi, “Pathogen recognition and innate immunity,” Cell, vol. 124, no. 4, pp. 783–801, 2006.
- J. P. Morth, B. P. Pedersen, M. J. Buch-Pedersen et al., “A structural overview of the plasma membrane Na+,K+-ATPase and H+-ATPase ion pumps,” Nature Reviews Molecular Cell Biology, vol. 12, no. 1, pp. 60–70, 2011.
- S. Lacroix-Lamandé, M. F. D'Andon, E. Michel et al., “Downregulation of the Na/K-ATPase pump by leptospiral glycolipoprotein activates the NLRP3 inflammasome,” Journal of Immunology, vol. 188, no. 6, pp. 2805–2814, 2012.